MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Ltd - Common Shares (NQ:TLSA)

1.510 -0.090 (-5.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,161
Open 1.590
Bid (Size) 1.400 (1,000)
Ask (Size) 1.480 (200)
Prev. Close 1.600
Today's Range 1.460 - 1.600
52wk Range 0.6302 - 2.600
Shares Outstanding 194,612,289
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Performance

YTD
-5.6%
-5.6%
1 Month
-5.6%
-5.6%
3 Month
-18.8%
-18.8%
6 Month
-38.4%
-38.4%
1 Year
+120.4%
+120.4%

More News

Read More
Tiziana Life Sciences Stock Rises On Advancing Second Asset Besides Foralumab: Retail Thinks Stock Has ‘So Much Potential’ ↗
Via Stocktwits
News headline image
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Elon Musk Says Tesla, xAI Are 'Trending Towards Convergence' In Some Ways ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Announces Purchase of Shares by Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
News headline image
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
From Tiziana Life Sciences Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is Tiziana Life Sciences Ltd - Common Shares publicly traded?
Yes, Tiziana Life Sciences Ltd - Common Shares is publicly traded.
What exchange does Tiziana Life Sciences Ltd - Common Shares trade on?
Tiziana Life Sciences Ltd - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Tiziana Life Sciences Ltd - Common Shares?
The ticker symbol for Tiziana Life Sciences Ltd - Common Shares is TLSA on the Nasdaq Stock Market
What is the current price of Tiziana Life Sciences Ltd - Common Shares?
The current price of Tiziana Life Sciences Ltd - Common Shares is 1.510
When was Tiziana Life Sciences Ltd - Common Shares last traded?
The last trade of Tiziana Life Sciences Ltd - Common Shares was at 01/30/26 04:00 PM ET
What is the market capitalization of Tiziana Life Sciences Ltd - Common Shares?
The market capitalization of Tiziana Life Sciences Ltd - Common Shares is 293.86M
How many shares of Tiziana Life Sciences Ltd - Common Shares are outstanding?
Tiziana Life Sciences Ltd - Common Shares has 294M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story